Lobaplatin

Lobaplatin (D-19466) is a diastereometric mixture of platinum (II) complexe. Lobaplatin arrests cell cycle at G1 and G2/M phase. Lobaplatin induces apoptosis by increasing expressions of caspase and Bax, decreasing expression of Bcl-2. Lobaplatin can be used for research of cancer[1][2][3].

Product Specifications

CAS Number

[135558-11-1]

Product Name Alternative

D-19466

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcl-2 Family; Caspase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lobaplatin.html

Purity

98.0

Solubility

DMSO : 4.55 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1[O-][Pt+2]2([O-]C1=O)[NH2]CC(CC3)C3C[NH2]2

Molecular Formula

C9H18N2O3Pt

Molecular Weight

397.33

Precautions

H302, H315, H319, H335

References & Citations

[1]Du L, et, al. Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio. Biomed Pharmacother. 2017 Nov;95:447-452.|[2]Wu Q, et, al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J Hematol Oncol. 2010 Oct 31;3:43.|[3]McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001 Jan;10 (1) :119-28.